Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
502948
Reference Type
Journal Article
Title
Predictive value of blood and bone marrow flow Cytometry in B-Cell lymphoma classification: Comparative analysis of flow Cytometry and tissue biopsy in 252 patients
Author(s)
Morice, WG; Kurtin, PJ; Hodnefield, JM; Shanafelt, TD; Hoyer, JD; Remstein, ED; Hanson, CA
Year
2008
Is Peer Reviewed?
1
Journal
Mayo Clinic Proceedings
ISSN:
0025-6196
EISSN:
1942-5546
Volume
83
Issue
7
Page Numbers
776-785
Language
English
Abstract
OBJECTIVE: To study the effectiveness of peripheral blood (PB) and bone marrow flow cytometric immunophenotyping (FCIP) in Predicting the histologic B-cell lymphoma type. PATIENTS AND METHODS: We studied the FCIP results and tissue histopathology from 252 patients with B-cell lymphoma seen at Mayo Clinic's site in Rochester, MN, between January 1, 19979 and January 1, 2004, who had positive results on PB, bone marrow, or body fluid FCIP and a corresponding diagnostic tissue biopsy specimen. RESULTS: Most of the B-cell lymphomas studied were low grade, with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma being most common. Flow cytometric immunophenotyping histogram analysis was more informative than tabulated percentage antigen positivity; surface immunoglobulin and CD20 staining intensity, CD5 and CD23 positivity, CD10 positivity, and the coexpression of CD11c/CD22 and CD103 were the most pertinent markers. Using these FCIP parameters and strict immuno-phenotypic definitions for CLL, mantle cell lymphoma (MCL), and hairy cell leukemia, we obtained greater than 95% specificity for each diagnosis. However, we encountered the following exceptions to standard paradigms of B-cell lymphoma-associated FCIP: (1) CD5 expression by disorders distinct from CLL and MCL, (2) lack of uniform CDS positivity in some CLL and MCL cases, (3) absence of CD10 in approximately 50% of follicular lymphomas, and (4) expression of CD103 by occasional marginal zone lymphomas. CONCLUSION: Stringent interpretation of PB and bone marrow FCIP results enables identification of certain B-cell lymphoma types. However, the observed exceptions to accepted immuno-phenotypic paradigms highlight the occasional phenotypic overlap among diseases and emphasize that a systematic approach to FCIP interpretations is key to providing clinically useful diagnostic information.
Keywords
chronic lymphoproliferative disorders; chronic lymphocytic-leukemia; immunophenotypic analysis; waldenstroms macroglobulinemia; malignant-lymphoma; peripheral-blood; scoring system; expression; diagnosis; cd10
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity